𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of amsacrine in patients with multiple myeloma

✍ Scribed by Greipp, Philip R. ;Coleman, Morton ;Anderson, Keaven ;McIntyre, O. Ross

Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
239 KB
Volume
17
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Seventy-four previously treated patients with multiple myeloma were treated with Amsacrine (m-AMSA) 120 mg/m2 every 3 weeks. A good response was observed in two patients (3%), and improvement was seen in three patients (4%). Severe toxicity was observed in 33% of patients who received three or more courses of treatment. This dose and schedule of m-AMSA in multiple myeloma is usually ineffective.

πŸ“œ SIMILAR VOLUMES

A Phase I–II trial of polyethylene glyco
A Phase I–II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma
✍ Neeraj R. Agrawal; Ronald M. Bukowski; Lisa A. Rybicki; Joanne Kurtzberg; Lewis πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 77 KB

## Abstract ## BACKGROUND Multiple myeloma remains an incurable disease. New agents are needed to improve therapy for patients with this disease. Previous investigators evaluated in vitro sensitivity of myeloma cells to polyethylene glycol‐conjugated L‐asparaginase (PEG‐L‐asparaginase) using the h

A Phase II trial of pegylated liposomal
A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients
✍ Mohamad A. Hussein; Laura Wood; Eric Hsi; Gordan Srkalovic; MaryAnn Karam; Paul πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 91 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Patients with multiple myeloma (MM) have increased bone marrow angiogenesis, a low plasma cell labeling index, and multidrug resistance (the primary cause of chemotherapy failure). MM patients receiving the vincristine, doxorubicin, and dexamethasone (VAD) regimen develop

Phase II trial of dimethyltriazenoimidaz
Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid
✍ Ronald M. Bukowski; Catherine M. Tangen; Robert F. Peterson; Thomas R. Fleming; πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 347 KB πŸ‘ 2 views

Background. The use of chemotherapy in patients with metastatic carcinoid tumors has been of limited value, and investigiition of new agents is necessary. Previous reports have suggested that dimethyltriazenoimidazole carboxamide (DTIC) may have antitumor activity. Methods. A Phase I1 trial to inve